Heuck 1997b.

Methods	Setting: Denmark, paediatric outpatient clinic Length of intervention period: 4 weeks Randomisation: yes, computer‐generated randomisation schedule Allocation concealment: unclear Design: crossover, 1 week washout period Masking: double blind Excluded: not stated Withdrawals: stated Baseline characteristics: comparable Jadad score=4
Participants	16 adolescents: 12M 4F Age range: 12.9‐16.6 years Inclusion criteria: Adolescents with mild to moderate asthma Requiring treatment with only beta2 agonists or low dose inhaled corticosteroids Exclusion criteria: Inhaled or oral steroids in month prior to study
Interventions	BUD: 200 mcg 2 actuations 2xdaily (800 mcg/d) Placebo: 2actuations 2xdaily Delivery device: MDI+Nebuhaler spacer
Outcomes	Lower leg growth velocity by knemometry Serum carboxy‐terminal propetide of type 1 collagen (PICP) Serum carboxy‐terminal pyridinioline cross‐liked telopeptide of type 1 collagen (ICTP) Amino‐terminal propeptide of type III procollagen (PIIINP) Urinary concentration pyridinoline crosslinks (PYD) Urinary concentration deoxypyridinoline crosslinks (DPD) Insulin‐like growth factor I (IGF‐I) Insulin‐like growth factor binding protein‐3 (IGFBP‐3) Morning PEFR Evening PEFR Daily use of beta2 agonists
Notes	No reply from author to clarify details of randomisation method.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear